<status value="active" /> <condition> <coding> <system value="http://fhir.de/CodeSystem/dimdi/icd-10-gm" /> <code value="C50" /> </coding> <text value="Bösartige Neubildung der Brustdrüse [Mamma]" /> </condition> <relatedArtifact> <type value="documentation" /> <label value="2016-004586-67" /> <display value="EudraCT" /> <url value="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004586-67" /> </relatedArtifact> <relatedArtifact> <type value="documentation" /> <label value="NCT03056755" /> <display value="ClinicalTrials.gov" /> <url value="https://clinicaltrials.gov/ct2/show/study/NCT03056755" /> </relatedArtifact> <keyword> <coding> <system value="https://fhir.uk-erlangen.de/CodeSystem/studyCategory" /> <code value="entgyn" /> </coding> <text value="Gynäkologische Tumore (z.B. Brustkrebs, Gebärmutterkrebs)" /> </keyword> <keyword> <coding> <system value="https://fhir.uk-erlangen.de/CodeSystem/studyCategory" /> <code value="gynmamma" /> </coding> <text value="Brustkrebs (Mammakarzinom)" /> </keyword> <description value="Eine multizentrische, offene, nicht-vergleichende Phase II-Studie mit zwei Kohorten zur Untersuchung der Wirksamkeit und Sicherheit von Alpelisib plus Fulvestrant oder Letrozol bei Patienten mit PIK3CA-mutierten, Hormonrezeptor positiven (HR+), HER2 negativen (HER2-) fortgeschrittenen Brustkrebs (aBC), die unter oder nach einer Therapie mit einem CDK4/6-Inhibitor einen Progress erlitten haben." /> <enrollment> <reference value="#1" /> </enrollment> <site> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteRecruitmentStatus"> <valueCodeableConcept> <coding> <system value="http://hl7.org/fhir/research-study-status" /> <code value="active" /> </coding> </valueCodeableConcept> </extension> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact"> <valueContactDetail> <name value="Studienzentrum Frauenklinik" /> <telecom> <system value="email" /> <value value="fk-studienzentrale@<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> <telecom> <system value="phone" /> <value value="+49 9131-<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> </valueContactDetail> </extension> <reference value="Location/1" /> </site> <site> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteRecruitmentStatus"> <valueCodeableConcept> <coding> <system value="http://hl7.org/fhir/research-study-status" /> <code value="active" /> </coding> </valueCodeableConcept> </extension> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact"> <valueContactDetail> <name value="C <REDACTED>" /> <telecom> <system value="email" /> <value value="studiensekretariat.gyn@<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> <telecom> <system value="phone" /> <value value="+49 351-<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> </valueContactDetail> </extension> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact"> <valueContactDetail> <name value="Dr. <REDACTED>" /> <telecom> <system value="email" /> <value value="<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> </valueContactDetail> </extension> <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact"> <valueContactDetail> <name value="Prof. Dr. med. <REDACTED>" /> <telecom> <system value="email" /> <value value="<REDACTED>" /> <use value="work" /> <rank value="1" /> </telecom> </valueContactDetail> </extension> <reference value="Location/8892" /> </site> </ResearchStudy>


  
  
    
      
      
      
      
      
      
        
          
            
            
          
        
        
          
            
            
            
          
        
        
      
    
  
  
    
  
  
    
    
    
  
  
    
    
    
  
  
    
    
    
  
  
    
    
    
  
  
    
    
    
  
  
  <status value="active" />
  <condition>
    <coding>
      <system value="http://fhir.de/CodeSystem/dimdi/icd-10-gm" />
      <code value="C50" />
    </coding>
    <text value="Bösartige Neubildung der Brustdrüse [Mamma]" />
  </condition>
  <relatedArtifact>
    <type value="documentation" />
    <label value="2016-004586-67" />
    <display value="EudraCT" />
    <url value="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004586-67" />
  </relatedArtifact>
  <relatedArtifact>
    <type value="documentation" />
    <label value="NCT03056755" />
    <display value="ClinicalTrials.gov" />
    <url value="https://clinicaltrials.gov/ct2/show/study/NCT03056755" />
  </relatedArtifact>
  <keyword>
    <coding>
      <system value="https://fhir.uk-erlangen.de/CodeSystem/studyCategory" />
      <code value="entgyn" />
    </coding>
    <text value="Gynäkologische Tumore (z.B. Brustkrebs, Gebärmutterkrebs)" />
  </keyword>
  <keyword>
    <coding>
      <system value="https://fhir.uk-erlangen.de/CodeSystem/studyCategory" />
      <code value="gynmamma" />
    </coding>
    <text value="Brustkrebs (Mammakarzinom)" />
  </keyword>
  <description value="Eine multizentrische, offene, nicht-vergleichende Phase II-Studie mit zwei Kohorten zur Untersuchung der Wirksamkeit und Sicherheit von Alpelisib plus Fulvestrant oder Letrozol bei Patienten mit PIK3CA-mutierten, Hormonrezeptor positiven (HR+), HER2 negativen (HER2-) fortgeschrittenen Brustkrebs (aBC), die unter oder nach einer Therapie mit einem CDK4/6-Inhibitor einen Progress erlitten haben." />
  <enrollment>
    <reference value="#1" />
  </enrollment>
  <site>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteRecruitmentStatus">
      <valueCodeableConcept>
        <coding>
          <system value="http://hl7.org/fhir/research-study-status" />
          <code value="active" />
        </coding>
      </valueCodeableConcept>
    </extension>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact">
      <valueContactDetail>
        <name value="Studienzentrum Frauenklinik" />
        <telecom>
          <system value="email" />
          <value value="fk-studienzentrale@<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
        <telecom>
          <system value="phone" />
          <value value="+49 9131-<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
      </valueContactDetail>
    </extension>
    <reference value="Location/1" />
  </site>
  <site>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteRecruitmentStatus">
      <valueCodeableConcept>
        <coding>
          <system value="http://hl7.org/fhir/research-study-status" />
          <code value="active" />
        </coding>
      </valueCodeableConcept>
    </extension>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact">
      <valueContactDetail>
        <name value="C <REDACTED>" />
        <telecom>
          <system value="email" />
          <value value="studiensekretariat.gyn@<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
        <telecom>
          <system value="phone" />
          <value value="+49 351-<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
      </valueContactDetail>
    </extension>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact">
      <valueContactDetail>
        <name value="Dr. <REDACTED>" />
        <telecom>
          <system value="email" />
          <value value="<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
      </valueContactDetail>
    </extension>
    <extension url="https://fhir.miracum.org/uc1/StructureDefinition/siteContact">
      <valueContactDetail>
        <name value="Prof. Dr. med. <REDACTED>" />
        <telecom>
          <system value="email" />
          <value value="<REDACTED>" />
          <use value="work" />
          <rank value="1" />
        </telecom>
      </valueContactDetail>
    </extension>
    <reference value="Location/8892" />
  </site>
</ResearchStudy>